Serodus AS
Testing fresh mechanisms to treat cardiovascular disorders
This article was originally published in Start Up
Executive Summary
The project that prompted the formation of Serodus AS is no longer the driving force of this start-up company. But the founding research did spark a deal that brought the firm a similar but more advanced asset, now one of three the firm is developing for cardiovascular indications ranging from high systolic blood pressure to atrial fibrillation to heart failure. Serodus in-licensed its lead candidate, a peptide classified as an opioid receptor agonist from Zealand Pharma, which took the compound through several clinical trials in both acute and chronic heart failure. Serodus thinks it could potentially develop a 5-HT-4 receptor antagonist it calls SER102 for atrial fibrillation that occurs in connection with surgery.
You may also be interested in...
Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart
Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.